α1-antitrypsin deficiency and lung disease: Risk modification by occupational and environmental inhalants

European Respiratory Journal

Volumn 26, Issue 5, 2005, Pages 909-917

  Senn, O ^a   Russi, E W ^b   Imboden, M ^a   Probst Hensch, Nicole M ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

1 antitrypsin; antitrypsin deficiency; Gene environment interaction; Occupational disorder; Occupational exposure; Passive smoking

Indexed keywords

ALPHA 1 ANTITRYPSIN; TOBACCO SMOKE;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLASSIFICATION; DIAGNOSTIC PROCEDURE; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENVIRONMENTAL EXPOSURE; EVIDENCE BASED MEDICINE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; LUNG DISEASE; LUNG FUNCTION; MEDLINE; OCCUPATIONAL EXPOSURE; PASSIVE SMOKING; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RISK MANAGEMENT; SAMPLE SIZE; SYMPTOMATOLOGY; AIR POLLUTANT; CLINICAL TRIAL; COMORBIDITY; INDOOR AIR POLLUTION; META ANALYSIS; METHODOLOGY; OCCUPATIONAL DISEASE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICS;

AIR POLLUTANTS; ALPHA 1-ANTITRYPSIN DEFICIENCY; CLINICAL TRIALS; COMORBIDITY; HUMANS; LUNG DISEASES; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TOBACCO SMOKE POLLUTION;

EID: 27744508591     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00021605     Document Type: Article

References (60)

1. Silverman EK, Chapman HA, Drazen JM, et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998; 157: 1770-1778.
2. Tishler PV, Carey VJ, Reed T, Fabsitz RR. The role of genotype in determining the effects of cigarette smoking on pulmonary function. Genet Epidemiol 2002; 22: 272-282.
3. Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. Acta Med Scand 1978; 204: 345-351.
4. Janus ED, Phillips NT, Carrell RW. Smoking, lung function, and alpha 1-antitrypsin deficiency. Lancet 1985; 1: 152-154.
5. Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest 1990; 85: 1343-1352.
6. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for the positive acute phase serum proteins, alpha1-acid glycoprotein (orosomucoid), alpha1-antitrypsin, and haptoglobin: a practical, simple, and clinically relevant approach in a large cohort. J Clin Lab Anal 2000; 14: 284-292.
7. Hill AT, Bayley DL, Campbell EJ, Hill SL, Stockley RA. Airways inflammation in chronic bronchitis: the effects of smoking and alpha1-antitrypsin deficiency. Eur Respir J 2000; 15: 886-890.
8. Kuhn CIII. The biochemical pathogenesis of chronic obstructive pulmonary diseases: protease-antiprotease imbalance in emphysema and diseases of the airways. J Thorac Imaging 1986; 1: 1-6.
9. Martin NG, Clark P, Ofulue AF, Eaves LJ, Corey LA, Nance WE. Does the PI polymorphism alone control alpha-1-antitrypsin expression? Am J Hum Genet 1987; 40: 267-277.
10. Silverman GA, Bird PI, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001; 276: 33293-33296.
11. Riva A, Kohane IS. SNPper: retrieval and analysis of human SNPs. Bioinformatics 2002; 18: 1681-1685.
12. Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1-antitrypsin deficiency. Am J Med 1988; 84: 13-31.
13. Faber JP, Poller W, Weidinger S, et al. Identification and DNA sequence analysis of 15 new alpha 1-antitrypsin variants, including two PI*Q0 alleles and one deficient PI*M allele. Am J Hum Genet 1994; 55: 1113-1121.
14. de Serres FJ. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002; 122: 1818-1829.
15. Lee JH, Brantly M. Molecular mechanisms of alpha1-antitrypsin null alleles. Respir Med 2000; 94: Suppl. C, S7-S11.
16. American Thoracic Society/European Respiratory Society Statement. Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency. Am J Respir Crit Care Med 2003; 168: 818-900.
17. Tobin MJ, Cook PJ, Hutchison DC. Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association. Br J Dis Chest 1983; 77: 14-27.
18. Seersholm N, Kok-Jensen A, Dirksen A. Decline in FEV1 among patients with severe hereditary alpha 1-antitrypsin deficiency type PiZ. Am J Respir Crit Care Med 1995; 152: 1922-1925.
19. Piitulainen E, Eriksson S. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ). Eur Respir J 1999; 13: 247-251.
20. Turino GM, Barker AF, Brantly ML, et al. Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1996; 154: 1718-1725.
21. Eriksson S, Lindell SE, Wiberg R. Effects of smoking and intermediate alpha 1-antitrypsin deficiency (PiMZ) on lung function. Eur J Respir Dis 1985; 67: 279-285.
22. Larsson C, Eriksson S, Dirksen H. Smoking and intermediate alpha1-antitrypsin deficiency and lung function in middle-aged men. Br Med J 1977; 2: 922-925.
23. Sandford AJ, Chagani T, Weir TD, Connett JE, Anthonisen NR, Pare PD. Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med 2001; 163: 469-473.
24. Seersholm N, Wilcke JT, Kok-Jensen A, Dirksen A. Risk of hospital admission for obstructive pulmonary disease in alpha(1)-antitrypsin heterozygotes of phenotype PiMZ. Am J Respir Crit Care Med 2000; 161: 81-84.
25. Hersh CP, Dahl M, Ly NP, Berkey CS, Nordestgaard BG, Silverman EK. Chronic obstructive pulmonary disease in {alpha}1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax 2004; 59: 843-849.
26. Silverman EK, Pierce JA, Province MA, Rao DC, Campbell EJ. Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates. Ann Intern Med 1989; 111: 982-991.
27. Piitulainen E, Tornling G, Eriksson S. Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha 1-antitrypsin deficiency (PiZZ). Thorax 1997; 52: 244-248.
28. Piitulainen E, Sveger T. Effect of environmental and clinical factors on lung function and respiratory symptoms in adolescents with alpha1-antitrypsin deficiency. Acta Paediatr 1998; 87: 1120-1124.
29. Piitulainen E, Tornling G, Eriksson S. Environmental correlates of impaired lung function in non-smokers with severe alpha 1-antitrypsin deficiency (PiZZ). Thorax 1998; 53: 939-943.
30. Mayer AS, Stoller JK, Bucher BB, James RA, Sandhaus RA, Newman LS. Occupational exposure risks in individuals with PI*Z alpha(1)-antitrypsin deficiency. Am J Respir Crit Care Med 2000; 162: 553-558.
31. Cole RB, Nevin NC, Blundell G, Merrett JD, McDonald JR, Johnston WP. Relation of alpha-1-antitrypsin phenotype to the performance of pulmonary function tests and to the prevalence of respiratory illness in a working population. Thorax 1976; 31: 149-157.
32. Chan-Yeung M, Ashley MJ, Corey P, Maledy H. Pi phenotypes and the prevalence of chest symptoms and lung function abnormalities in workers employed in dusty industries. Am Rev Respir Dis 1978; 117: 239-245.
33. Ostrow DN, Manfreda J, Dorman T, Cherniack RM. Alpha1-antitrypsin phenotypes and lung function in a moderately polluted northern Ontario community. Can Med Assoc J 1978; 118: 669-672.
34. Beckman G, Beckman L, Mikaelsson B, Rudolphi O, Stjernberg N, Wiman LG. Alpha-1-antitrypsin types and chronic obstructive lung disease in an industrial community in Northern Sweden. Hum Hered 1980; 30: 299-306.
35. Stjernberg N, Beckman G, Beckman L, Nystrom L, Rosenhall L. Alpha-1-antitrypsin types and pulmonary disease among employees at a sulphite pulp factory in northern Sweden. Hum Hered 1984; 34: 337-342.
36. Horne SL, Tennent RK, Cockcroft DW, Cotton DJ, Dosman JA. Pulmonary function in Pi M and MZ grainworkers. Chest 1986; 89: 795-799.
37. Pierre F, Pham QT, Mur JM, Chau N, Martin JP. Respiratory symptoms and pulmonary function in 871 miners according to Pi phenotype: a longitudinal study. Eur J Epidemiol 1988; 4: 39-44.
38. Sigsgaard T, Brandslund I, Rasmussen JB, Lund ED, Varming H. Low normal alpha-1-antitrypsin serum concentrations and MZ-phenotype are associated with byssinosis and familial allergy in cotton mill workers. Pharmacogenetics 1994; 4: 135-141.
39. Sigsgaard T, Brandslund I, Omland O, et al. S and Z alpha1-antitrypsin alleles are risk factors for bronchial hyperresponsiveness in young farmers: an example of gene/environment interaction. Eur Respir J 2000; 16: 50-55.
40. Lafuente MJ, Casterad X, Laso N, et al. Pi*S and Pi*Z alpha 1 antitrypsin polymorphism and the risk for asbestosis in occupational exposure to asbestos. Toxicol Lett 2002; 136: 9-17.
41. von Ehrenstein OS, von Mutius E, Maier E, et al. Lung function of school children with low levels of alpha1-antitrypsin and tobacco smoke exposure. Eur Respir J 2002; 19: 1099-1106.
42. Corbo GM, Forastiere F, Agabiti N, et al. Passive smoking and lung function in alpha(1)-antitrypsin heterozygote schoolchildren. Thorax 2003; 58: 237-241.
43. Wadsworth ME, Vinall LE, Jones AL, et al. Alpha1-antitrypsin as a risk for infant and adult respiratory outcomes in a national birth cohort. Am J Respir Cell Mol Biol 2004; 31: 559-564.
44. Morgan K, Scobie G, Marsters P, Kalsheker NA. Mutation in an alpha1-antitrypsin enhancer results in an interleukin-6 deficient acute-phase response due to loss of cooperativity between transcription factors. Biochim Biophys Acta 1997; 1362: 67-76.
45. Barker AF, Iwata-Morgan I, Oveson L, Roussel R. Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency. Chest 1997; 112: 607-613.
46. Brantly ML, Wittes JT, Vogelmeier CF, Hubbard RC, Fells GA, Crystal RG. Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes. Chest 1991; 100: 703-708.
47. Mahadeva R, Atkinson C, Li Z, et al. Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol 2005; 166: 377-386.
48. Curiel DT, Vogelmeier C, Hubbard RC, Stier LE, Crystal RG. Molecular basis of alpha 1-antitrypsin deficiency and emphysema associated with the alpha 1-antitrypsin Mmineral springs allele. Mol Cell Biol 1990; 10: 47-56.
49. Mulgrew AT, Taggart CC, Lawless MW, et al. Z alpha1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. Chest 2004; 125: 1952-1957.
50. Hubbard RC, Ogushi F, Fells GA, et al. Oxidants spontaneously released by alveolar macrophages of cigarette smokers can inactivate the active site of alpha 1-antitrypsin, rendering it ineffective as an inhibitor of neutrophil elastase. J Clin Invest 1987; 80: 1289-1295.
51. Fera T, Abboud RT, Johal SS, Richter AM, Gibson N. Effect of smoking on functional activity of plasma alpha 1-protease inhibitor. Chest 1987; 91: 346-530.
52. Ogushi F, Hubbard RC, Vogelmeier C, Fells GA, Crystal RG. Risk factors for emphysema. Cigarette smoking is associated with a reduction in the association rate constant of lung alpha 1-antitrypsin for neutrophil elastase. J Clin Invest 1991; 87: 1060-1065.
53. Kalsheker NA, Morgan K. Regulation of the alpha 1-antitrypsin gene and a disease-associated mutation in a related enhancer sequence. Am J Respir Crit Care Med 1994; 150: S183-S189.
54. Dhami R, Gilks B, Xie C, Zay K, Wright JL, Churg A. Acute cigarette smoke-induced connective tissue breakdown is mediated by neutrophils and prevented by alpha1-antitrypsin. Am J Respir Cell Mol Biol 2000; 22: 244-252.
55. Spencer LT, Paone G, Krein PM, Rouhani FN, Rivera-Nieves J, Brantly ML. Role of human neutrophil peptides in lung inflammation associated with alpha1-antitrypsin deficiency. Am J Physiol Lung Cell Mol Physiol 2004; 286: L514-L520.
56. Kunzli N, Kaiser R, Medina S, et al. Public-health impact of outdoor and traffic-related air pollution: a European assessment. Lancet 2000; 356: 795-801.
57. The International HapMap Project. Nature 2003; 426: 789-796.
58. Byth BC, Billingsley GD, Cox DW. Physical and genetic mapping of the serpin gene cluster at 14q32.1: allelic association and a unique haplotype associated with alpha 1-antitrypsin deficiency. Am J Hum Genet 1994; 55: 126-133.
59. Novoradovsky A, Brantly ML, Waclawiw MA, et al. Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in alpha1-antitrypsin deficiency. Am J Respir Cell Mol Biol 1999; 20: 441-447.
60. Rodriguez F, de la Roza C, Jardi R, Schaper M, Vidal R, Miravitlles M. Glutathione S-transferase P1 and lung function in patients with alpha1-antitrypsin deficiency and COPD. Chest 2005; 127: 1537-1543.